Literature DB >> 9133555

Increased renal production of transforming growth factor-beta1 in patients with type II diabetes.

K Sharma1, F N Ziyadeh, B Alzahabi, T A McGowan, S Kapoor, B R Kurnik, P B Kurnik, L S Weisberg.   

Abstract

Diabetic nephropathy is a common complication in patients with either type I or type II diabetes. The pathogenesis of diabetic nephropathy is thought to involve both metabolic and vascular factors leading to chronic accumulation of glomerular mesangial matrix. In this context, both transforming growth factor-beta (TGF-beta) and endothelin may contribute to these processes. To determine if diabetic patients demonstrate increased renal production of TGF-beta and endothelin, aortic, renal vein, and urinary levels of these factors were measured in 14 type II diabetic patients and 11 nondiabetic patients who were undergoing elective cardiac catheterization. Renal blood flow was measured in all patients to calculate net mass balance across the kidney. Diabetic patients demonstrated net renal production of immunoreactive TGF-beta1 (830 +/- 429 ng/min [mean +/- SE]), whereas nondiabetic patients demonstrated net renal extraction of circulating TGF-beta1 (-3479 +/- 1010 ng/min, P < 0.001). Urinary levels of bioassayable TGF-beta were also significantly increased in diabetic patients compared with nondiabetic patients (2.435 +/- 0.385 vs. 0.569 +/- 0.190 ng/mg creatinine, respectively; P < 0.001). Renal production of immunoreactive endothelin was not significantly increased in diabetic patients. In summary, type II diabetes is associated with enhanced net renal production of TGF-beta1, whereas nondiabetic patients exhibit net renal extraction of circulating TGF-beta1. Increased renal TGF-beta production may be an important manifestation of diabetic kidney disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9133555     DOI: 10.2337/diab.46.5.854

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  69 in total

1.  Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy.

Authors:  F Lang; K Klingel; C A Wagner; C Stegen; S Warntges; B Friedrich; M Lanzendorfer; J Melzig; I Moschen; S Steuer; S Waldegger; M Sauter; M Paulmichl; V Gerke; T Risler; G Gamba; G Capasso; R Kandolf; S C Hebert; S G Massry; S Broër
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Transforming growth factor beta contributes to progressive diabetic nephropathy.

Authors:  W B Reeves; T E Andreoli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

3.  Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1.

Authors:  M H Poczatek; C Hugo; V Darley-Usmar; J E Murphy-Ullrich
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

4.  Pirfenidone for diabetic nephropathy.

Authors:  Kumar Sharma; Joachim H Ix; Anna V Mathew; Monique Cho; Axel Pflueger; Stephen R Dunn; Barbara Francos; Shoba Sharma; Bonita Falkner; Tracy A McGowan; Michael Donohue; Satish Ramachandrarao; Ronghui Xu; Fernando C Fervenza; Jeffrey B Kopp
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

5.  TGFβ acts through PDGFRβ to activate mTORC1 via the Akt/PRAS40 axis and causes glomerular mesangial cell hypertrophy and matrix protein expression.

Authors:  Soumya Maity; Falguni Das; Balakuntalam S Kasinath; Nandini Ghosh-Choudhury; Goutam Ghosh Choudhury
Journal:  J Biol Chem       Date:  2020-07-30       Impact factor: 5.157

6.  Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway.

Authors:  Guihua Zhou; Cai Li; Lu Cai
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 7.  Angiotensin II and the glomerulus: focus on diabetic kidney disease.

Authors:  James W Scholey
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

8.  Increased atherosclerosis in mice with increased vascular biglycan content.

Authors:  Joel C Thompson; Tao Tang; Patricia G Wilson; Meghan H Yoder; Lisa R Tannock
Journal:  Atherosclerosis       Date:  2014-04-15       Impact factor: 5.162

9.  Role of upstream stimulatory factor 2 in diabetic nephropathy.

Authors:  Shuxia Wang
Journal:  Front Biol (Beijing)       Date:  2015-05-13

Review 10.  Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.